LEXINGTON, Mass., Nov. 12,
2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN),
an immuno-oncology (I-O) company with a
pipeline of immune checkpoint antibodies,
adoptive cell therapies1 and cancer vaccines,
announced that it will host an R&D Day on November 15, 2019.
Date: Friday, November 15, 2019
Time: 11:00AM – 2:00PM
Live webcast: https://stream.rampard.com/20191115/index.jsp
Location: New York, NY (by
invitation only)
Agenus has delivered more I-O discoveries to the clinic in the
last three years than any large pharma and is on track to file a
BLA in 2020 for accelerated approval of its lead candidates
Zalifrelimab (anti-CTLA-4) and Balstilimab (anti-PD-1) while also
advancing AGEN1181, a potential best-in-class next generation
anti-CTLA-4 antibody, and a pipeline of additional antibodies, cell
therapies, and vaccines.
The event will be moderated by Dr. Garo
Armen, Chairman and Chief Executive Officer, and Dr.
Jennifer Buell, Chief Operating
Officer, and will include presentations by world experts in I-O,
Dr. Steven O'Day, Executive Director
of the John Wayne Cancer Institute, and Dr. Manuel Hidalgo, Chief of the Division of
Hematology and Medical Oncology at Weill Cornell Medicine and New
York-Presbyterian/Weill Cornell Medical Center.
The event will be webcast live and may be accessed by visiting
the "Events & Presentations" page within the Investors section
of the Agenus website www.agenusbio.com or by using the
link below. A replay of the webcast will be available on the Agenus
website following the event.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy with combination approaches that leverage
a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary) and its
proprietary cancer vaccine platforms. Agenus has a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
About AgenTus Therapeutics, Inc.
AgenTus
Therapeutics, a subsidiary of Agenus, is a preclinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of breakthrough "living drugs" to advance
potential cures for cancer patients. AgenTus employs
naturally-derived and engineered receptors, specifically T cell
receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to
supercharge human immune effector cells to seek and destroy cancer.
AgenTus also aims to advance adoptive cell therapy formats which
would enable off-the-shelf living drugs. AgenTus has locations in
Lexington, MA and Cambridge, UK. For more information, please
visit www.agentustherapeutics.com.
Forward-Looking Statements
This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding Agenus' clinical development and regulatory
plans and timelines and its upcoming R&D Day event. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics,
a subsidiary of Agenus
View original
content:http://www.prnewswire.com/news-releases/agenus-to-host-rd-day-november-15-2019-300956614.html
SOURCE Agenus Inc.